Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
New Jersey Legislators Approve Medical Marijuana Bill
New Jersey's legislatures passed a medical marijuana bill on Jan. 11. It has been signed into law, making New Jersey the 14th state in the union to permit the use of marijuana for medicinal purposes. In a release by the New Jersey Senate Democrats announcing the bill's passage, one of the bill's co-sponsors, Sen. Nicholas P. Scutari, says, “New Jersey has a demonstrated record of being tough on illegal drug use and the underground drug trade. However, when it comes to medical marijuana, we're not talking about hardened criminals, but individuals looking for some small bit of relief from chronic pain and debilitating illness. New Jersey has no interest in treating these folks like drug kingpins, and should provide legal access to medical marijuana for New Jerseyans who need it.” The New Jersey Compassionate Use Medical Marijuana Act provides for patients with State-issued ID cards to obtain marijuana from special dispensaries when their physicians prescribe it. These individuals are not permitted to grow their own supplies, and they may only use two ounces of the drug per month. Rules for opening, registering and operating treatment centers are also included in the law. Patients are eligible for the ID cards if they have one or more of the legislation's enumerated “debilitating conditions,” such as glaucoma or cancer. Specifically not included in the law were more nebulous medical complaints, like anxiety, which are so broad that they have led to abuses in other states that permit the use of medical marijuana.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
This article explores legal developments over the past year that may impact compliance officer personal liability.